The US District Court for the Northern District of Georgia dismisses the FTC’s "pay-for-delay" antitrust lawsuit ruling that the contested settlements are not an unreasonable restraint of trade (Androgel Litigation)

On February 22, 2010, Judge Thomas W. Thrash, Jr. dismissed the Federal Trade Commission’s (FTC) antitrust lawsuit alleging that Solvay Pharmaceuticals (Solvay) conspired with generic drug makers Watson Pharmaceuticals (Watson) and Par Pharmaceuticals (Par) to delay generic competition for the leading testosterone gel product Androgel. [1] The ruling represents a setback to the FTC’s aggressive campaign against so-called “pay-for-delay” patent settlements. Background The Androgel litigation challenges the settlement of patent litigation between branded drug manufacturer Solvay and generic drug producers Watson and Par (together, the defendants) relating to Solvay’s patent covering Androgel. Pursuant to the

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteurs

  • Skadden, Arps, Slate, Meagher & Flom (Washington DC)
  • Skadden, Arps, Slate, Meagher & Flom (Washington DC)
  • Fordham Competition Law Institute - FCLI (New York)

Citation

Gary A. MacDonald, Steven C. Sunshine, James A. Keyte, The US District Court for the Northern District of Georgia dismisses the FTC’s "pay-for-delay" antitrust lawsuit ruling that the contested settlements are not an unreasonable restraint of trade (Androgel Litigation), 22 février 2010, e-Competitions February 2010, Art. N° 45522

Visites 355

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues